KNP 302
Alternative Names: C3b inhibitor-CD59; KNP-302Latest Information Update: 29 Sep 2020
At a glance
- Originator Kanaph Therapeutics
- Class Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action CD59 antigen replacements; Complement C3b inactivator protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Immunological disorders
Most Recent Events
- 29 Sep 2020 Preclinical trials in Immunological disorders in South Korea (Parenteral) (Kanaph Therapeutics pipeline, September 2020)
- 28 Sep 2020 Preclinical trials in Dry age-related macular degeneration in South Korea (Parenteral) (Kanaph Therapeutics pipeline, September 2020)